Gapping down
In reaction to disappointing earnings/guidance:
- KSS -14.6%, (lowers FY17 guidance to $3.60-3.65 from $3.80-4.00 vs $3.93 Capital IQ Consensus Estimate; Nov-Dec comps -2.1%), RECN -13.2%
- M -11.2%, (Macy's lowers FY17 EPS; comparable sales on an owned plus licensed basis declined by 2.1 percent in the months of November and December 2016; announces actions to streamline store portfolio, intensify cost efficiency efforts and execute real estate strategy)
- MG -8.8%, LB -5.5%, MC -5.4%, (Moelis sees Q4 revs above consensus; raises dividend to $0.37/share from $0.32/share; commenced public offering of 5,000,000 shares of Class A common stock)
- CATO -5.4%, AEO -4.8%, RPM -1.5%,
Select retail related names showing weakness following Macy's and Kohl's comps:
- JWN -7.5%, JCP -5.4%, FOSL -4.6%, DDS -3.9%
Other news:
- AEZS -32.7% (reports the confirmatory Phase 3 clinical trial of Macrilen (macimorelin) failed to achieve its objective of validating a single oral dose of macimorelin for the evaluation of growth hormone deficiency in adults )
- HRTX -9.7% (announces 'positive' topline results from its Phase 2 study of HTX-011 in subjects undergoing abdominoplasty; 'demonstrated statistically significant reductions in both pain intensity and the use of opioid rescue medications through 96 hours following surgery'
- KNOP -8.5% (commences 2.5 mln common units offering)
- OREX -8.5% (after 64% move higher on Wednesday)
- HLX -5.1% (Helix Energy commences public offering of 21 mln shares of common stock; discloses impairment charge and delayed in-service for Siem Helix 1 update), BKE -3.4% (reports December comps of -15.5% vs -5.4% year ago and -16.2% last month
- KRC -1.5% (commences 3.5 mln common stock offering)
- HPP -1.3% (announced offering of 18,673,808 shares of common stock pursuant to an effective shelf registration statement )
- LOXO -1.2% (prices 3.87 mln common stock offering at $31.00/share)
Analyst comments:
- UAL -1.9% (downgraded to Equal-Weight from Overweight at Morgan Stanley)